Table 3.
Summary of included studies of patients with LVADs using SGLT2-i.
| Study | Study Design | Follow-Up | Dose | Duration of SGLT2-i (Days) |
Device Strategy |
|---|---|---|---|---|---|
| Cagliostro et al., 2022 [7] | Retrospective study | 30 days, 60 days, and 180 days |
- | - | BTT: 11 (35.5%) DT: 20 (64.5%) |
| Chavali et al., 2023 [5] | Retrospective study | - | - | 101.5 (37.5–190.8) | BTT |
| Moady et al., 2023 [6] | Observational study | 6 months | 10 mg once daily | - | - |
| Fardman et al., 2024 [21] | Retrospective study | 6 months | 10 mg once daily | - | - |
| Conference abstracts | |||||
| Lanham et al., 2023 [19] | Case report | - | - | - | - |
| Acosta et al., 2022 [14] | Retrospective study | - | - | - | - |
| Yaranov et al., 2022 [17] | - | - | - | - | - |
| Chavali et al., 2022 [15] | - | - | - | - | BTT |
| Hambright et al., 2022 [16] | Retrospective study | 3 months | - | - | - |
| Byczkowska et al., 2023 [18] | - | 3 months 1 year |
- | - | - |
| Al Ali et al., 2024 [20] | Retrospective study | - | - | - | - |
Data are presented as numbers (percentages), median (IQR). Abbreviations: BTT: Bridge-To-Transplant; DT: Destination Therapy; IQR: Interquartile Range.